

Astaxanthin in Disease Prevention and Treatment

Jun WANG¹ and Yan ZHAO^{1,a,*}

¹Department of Bioengineering, Harbin Institute of Technology, Weihai, Shandong, P. R. China.

^azhaoyan@hitwh.edu.cn

*Corresponding author

Keywords: Astaxanthin, Cardiovascular diseases, cancer, Diabetes, Neurodegenerative diseases.

Abstract. Astaxanthin is a carotenoid with strong antioxidant activity. The function of astaxanthin has been associated with a number of health-promoting benefits. This paper discusses the beneficial effects of astaxanthin in the prevention and treatment of human diseases such as cardiovascular diseases, cancer, diabetes and neurodegenerative diseases.

Introduction

Astaxanthin is a ketocarotenoid with strong antioxidant activity, which belongs to the family of xanthophylls [1, 2]. It occurs naturally in a wide variety of organisms such as microalgae, yeast, salmon, trout, shrimp and crayfish. The function of astaxanthin has been associated with a number of health-promoting benefits. This paper reviews the beneficial effects of astaxanthin in the prevention and treatment of human diseases such as cardiovascular diseases, cancer, diabetes, mellitus antidiabetic, and neurodegenerative diseases.

Astaxanthin and Cardiovascular Disease

Astaxanthin has been regarded as a potential treatment for cardiovascular diseases [3]. Both *in vitro* and *in vivo* studies show that astaxanthin can reduce the oxidation of low density lipoprotein (LDL) [4]. Astaxanthin also dose-dependently reduces the levels of triglyceride and increases serum high density lipoprotein (HDL)-cholesterol and adiponectin, which is a protein hormone modulating a number of metabolic processes including glucose regulation and fatty acid oxidation [5]. The disruption of mitochondrial membrane potential (MMP) is associated with apoptosis in cardiac cells. Astaxanthin elevates the MMP in heart dose-dependently, attenuating the release of cytochrome c from mitochondria and thereby inhibiting apoptosis and contractile failure and consequently improving cardiac function [6]. Oxidative stress and inflammation are strongly linked to the development of cardiovascular diseases. Study has shown that astaxanthin inhibits the inflammation and oxidative stress in human umbilical vein endothelial cells [7]. In stroke-prone hypertensive rats, it has been found that astaxanthin suppresses blood pressure and inhibits thrombosis in cerebral vessels [8]. Therefore, astaxanthin may contribute to the prevention of atherosclerosis and cardiovascular disease by regulating the levels of LDL and HDL and by reducing blood pressure, inflammation and oxidative stress.

Astaxanthin and Cancer

Astaxanthin has been shown to have anti-cancer effects [9]. In gastric cancer cell

model, astaxanthin inhibited cell proliferation through extracellular regulated protein kinases (ERK)-mediated cell cycle interruption. In hepatoma cells, astaxanthin not only disturbed the cell cycle, but also induced cell apoptosis [10]. In lung cancer cells, astaxanthin increased the apoptosis induced by chemotherapeutic agent mitomycin C by suppressing the activation of Akt and Rad51[11]. In a hamster oral cancer model, astaxanthin modulated the Nuclear factor- κ B (NF- κ B) and Wnt/ β -catenin pathways, causing the apoptosis in the buccal pouch tissue[12]. It was also demonstrated in hamster oral cancer model that astaxanthin interrupted cell proliferation via STAT-3-mediated decrease of cyclin D1 levels and increase of p21 expression while impeding the cell invasion by suppressing the expression of matrix metalloproteinases-2 (MMP-2) [13]. Similarly, astaxanthin alleviated the invasion of colon cancer induced by dimethyl hydrazine in Wistar rats by reducing the expression of MMP-2[14]. Overall, astaxanthin inhibits tumorigenesis by interruption of cell proliferation, promotion of apoptosis and decrease of cell invasion.

Astaxanthin and Diabetes

The major pathological feature of diabetes mellitus is impaired insulin secretion/sensitivity and the disease is frequently diagnosed by hyperglycemia, lipid abnormalities and vascular complications. In diabetic db/db mice, astaxanthin can attenuate blood glucose levels [15]. The immune dysfunction and oxidative stress are common in diabetic patients. In diabetic rats, the activities of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and the levels of glutathione in liver are significantly decreased, which can be reversed by astaxanthin treatment [16]. In diabetic lymphocytes, astaxanthin can alleviate lymphocyte dysfunctions by significantly decreasing the production of NO^* and $\text{O}_2^{\cdot-}$ and reducing the cytosolic Ca^{2+} [17]. In diabetes, major damage occurs in tissues such as kidney, astaxanthin can protect cell damages in the diabetic kidney[18]. In the kidneys of astaxanthin fed diabetic mice, cells positive for 8-hydroxydeoxyguanosine(8-OHdG), an index of oxidative stress, were significantly decreased, thus leading to the prevention of diabetic nephropathy[15]. One of the pathogenic factors of cardiovascular complications in diabetes is glycemic fluctuation. In endothelial cells, astaxanthin suppressed glucose fluctuation-induced signals such as the activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase, so astaxanthin may have protective effects against glucose fluctuation-induced endothelial dysfunction[19].

Astaxanthin and Neurodegenerative Diseases

Oxidative stress has been implicated in the pathogenesis of neurodegenerative disease. By reducing oxidative stress, astaxanthin has been shown to protect neuronal cells from reactive oxygen species-mediate toxicity [20], and decrease ischemia/reperfusion-induced hippocampal pyramidal neuron loss and learning and memory deficits [21]. Astaxanthin has also been shown to inhibit aluminum-induced activation of glial cells and generation of reactive oxygen species, consequently improving the spatial memory and locomotor activity in aluminum-treated animals [22]. In neuronal cell model and primary hippocampal neurons, astaxanthin can reduce the toxicity of β -amyloid ($\text{A}\beta$), which plays an important role in the pathogenesis of Alzheimer's disease (AD), by alleviating the oxidative stress induced by $\text{A}\beta$ [23]. 1-methyl-4-phenylpyridinium ion (MPP^+) is a neurotoxin that damages dopamine absorption and stimulates dopaminergic neuronal death, leading to Parkinson's disease-like syndrome. Astaxanthin has been shown to protect against

MPP⁺-induced oxidative stress and cell damages in both cell and animal models[24, 25]. Thus, astaxanthin may be a potential therapeutic agent in neurodegenerative diseases [26].

Astaxanthin and Other Disease

It has also been demonstrated that astaxanthin may be beneficial to a number of other disease conditions such as nonalcoholic fatty liver disease, lung fibrosis and acute kidney injury. The dysregulation of fibrogenesis in hepatic stellate cells is a common feature of non-alcoholic fatty liver. In human hepatic stellate cell line LX-2 cells and primary mouse hepatic stellate cells, astaxanthin inhibited fibrogenesis through attenuating cell signals mediated by fibrogenic cytokine transforming growth factor β 1 (TGF β 1) [27]. In high-fat-fed mice, astaxanthin administration reduced hepatic lipid accumulations and attenuated hepatic autophagy possibly via activating peroxisome proliferator-activated receptor alpha and inhibiting peroxisome proliferator-activated receptor gamma [28]. Astaxanthin also inhibited apoptosis induced by reactive oxygen species in animal models of lung fibrosis and acute kidney injury, alleviating these pathologic conditions [29, 30].

Summary

In summary, astaxanthin has beneficial effects in a number of human diseases. And astaxanthin may have therapeutic potential for prevention and treatment of these diseases.

Acknowledgement

This work is supported by grants from the National Natural Science Foundation of China (31201338), Shandong province key R & D Program project (2015GSF115014), research fund from Harbin Institute of Technology at Weihai [HIT(WH)Y200902] and Weihai Science and Technology Development Program (2009-3-93).

References

- [1] Edge, R., McGarvey, D.J., Truscott, T.G., The carotenoids as anti-oxidants - A review. *J. Photochem. Photobiol. B Biol.* 41 (1997) 189–200.
- [2] Naguib, Y.M., Antioxidant activities of astaxanthin and related carotenoids. *J. Agric. Food Chem.* 48(2000) 1150–1154.
- [3] Pashkow, F.J., Watumull, D.G., Campbell, C.L., Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease. *Am. J. Cardiol.* 101 (2008) 58D–68D.
- [4] Iwamoto, T., Hosoda, K., Hirano, R., Kurata, H., et al., Inhibition of low-density lipoprotein oxidation by astaxanthin. *J. Atheroscler. Thromb.* 7(2000) 216–222.
- [5] Yoshida, H., Yanai, H., Ito, K., Tomono, Y., et al., Administration of natural astaxanthin increases serum HDL-cholesterol and adiponectin in subjects with mild hyperlipidemia. *Atherosclerosis* 209 (2010) 520–523.

- [6] Nakao, R., Nelson, O.L., Park, J.S., Mathison, B.D., et al., Effect of astaxanthin supplementation on inflammation and cardiac function in BALB/c mice. *Anticancer Res.*30 (2010) 2721–2725.
- [7] Chew, W., Mathison, B., Kimble, L., Mixter, P., et al., Astaxanthin decreases inflammatory biomarkers associated with cardiovascular disease in human umbilical vein endothelial cells. *Am. J. Adv. Food Sci. Technol.* 1 (2013) 1–14.
- [8] Sasaki, Y., Kobara, N., Higashino, S., Giddings, J.C., et al., Astaxanthin inhibits thrombosis in cerebral vessels of stroke-prone spontaneously hypertensive rats. *Nutr. Res.*31 (2011) 784–789.
- [9] Zhang, L., Wang, H., Multiple mechanisms of anti-cancer effects exerted by astaxanthin. *Mar. Drugs*13(2015) 4310–4330.
- [10] Shao, Y., Ni, Y., Yang, J., Lin, X., et al., astaxanthin inhibits proliferation and Induces apoptosis and cell cycle arrest of mice H22 hepatoma cells. *Med. Sci. Monit.*22 (2016) 2152–60.
- [11] Ko, J.-C., Chen, J.-C., Wang, T.-J., Zheng, H.-Y., et al., Astaxanthin down-regulates Rad51 expression via inactivation of AKT kinase to enhance mitomycin C-induced cytotoxicity in human non-small cell lung cancer cells. *Biochem. Pharmacol.*105 (2016) 91–100.
- [12] Kavitha, K., Kowshik, J., Kishore, T.K.K., Baba, A.B., et al., Astaxanthin inhibits NF- κ B and Wnt/ β -catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. *Biochim. Biophys. Acta - Gen. Subj.*1830 (2013) 4433–4444.
- [13] Kowshik, J., Baba, A.B., Giri, H., Deepak Reddy, G., et al., Astaxanthin inhibits JAK/STAT-3 signaling to abrogate cell proliferation, invasion and angiogenesis in a hamster model of oral cancer. *PLoS One*9 (2014) e109114.
- [14] Nagendraprabhu, P., Sudhandiran, G., Astaxanthin inhibits tumor invasion by decreasing extracellular matrix production and induces apoptosis in experimental rat colon carcinogenesis by modulating the expressions of ERK-2, NF κ B and COX-2. *Invest. New Drugs*29 (2011) 207–224.
- [15] Naito, Y., Uchiyama, K., Aoi, W., Hasegawa, G., et al., Prevention of diabetic nephropathy by treatment with astaxanthin in diabetic db/db mice. *BioFactors*20(2004) 49–59.
- [16] Sila, A., Kamoun, Z., Ghliissi, Z., Makni, M., et al., Ability of natural astaxanthin from shrimp by-products to attenuate liver oxidative stress in diabetic rats. *Pharmacol. Reports*67(2015) 310–316.
- [17] Otton, R., Marin, D.P., Bolin, A.P., Santos, R. de C.M. dos, et al., Astaxanthin ameliorates the redox imbalance in lymphocytes of experimental diabetic rats. *Chem. Biol. Interact.*186 (2010) 306–315.
- [18] Sila, A., Ghliissi, Z., Kamoun, Z., Makni, M., et al., Astaxanthin from shrimp by-products ameliorates nephropathy in diabetic rats. *Eur. J. Nutr.*54 (2014) 301–307.
- [19] Abdelzaher, L.A., Imaizumi, T., Suzuki, T., Tomita, K., et al., Astaxanthin alleviates oxidative stress insults-related derangements in human vascular endothelial cells exposed to glucose fluctuations. *Life Sci.*150(2016) 24–31.

- [20] Chan, K.C., Mong, M.C., Yin, M.C., Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and canthaxanthin in nerve growth factor differentiated PC12 cells. *J. Food Sci.*74 (2009) 225–231.
- [21] Xue, Y., Qu, Z., Fu, J., Zhen, J., et al., The protective effect of astaxanthin on learning and memory deficits and oxidative stress in a mouse model of repeated cerebral ischemia/reperfusion. *Brain Res. Bull.*131(2017) 221–228.
- [22] Al-Amin, M.M., Reza, H.M., Saadi, H.M., Mahmud, W., et al., Astaxanthin ameliorates aluminum chloride-induced spatial memory impairment and neuronal oxidative stress in mice. *Eur. J. Pharmacol.*777(2016) 60–69.
- [23] Lobos, P., Bruna, B., Cordova, A., Barattini, P., et al., Astaxanthin protects primary hippocampal neurons against noxious Effects of A β -oligomers. *Neural Plast.*1 (2016) 3456783.
- [24] Lee, D.H., Kim, C.S., Lee, Y.J., Astaxanthin protects against MPTP/MPP⁺-induced mitochondrial dysfunction and ROS production in vivo and in vitro. *Food Chem. Toxicol.*49(2011) 271–280.
- [25] Ye, Q., Huang, B., Zhang, X., Zhu, Y., et al., Astaxanthin protects against MPP⁺-induced oxidative stress in PC12 cells via the HO-1/NOX2 axis. *BMC Neurosci.*13(2012) 156.
- [26] Grimmig, B., Kim, S.-H., Nash, K., Bickford, P.C., et al., Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration. *GeroScience*39(2017) 19–32.
- [27] Yang, Y., Kim, B., Park, Y.-K., Koo, S.I., et al., Astaxanthin prevents TGF β 1-induced pro-fibrogenic gene expression by inhibiting Smad3 activation in hepatic stellate cells. *Biochim. Biophys. Acta*1850(2015)178–185.
- [28] Jia, Y., Wu, C., Kim, J., Kim, B., et al., Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt. *J. Nutr. Biochem.*28 (2016) 9–18.
- [29] Song, X., Wang, B., Lin, S., Jing, L., et al., Astaxanthin inhibits apoptosis in alveolar epithelial cells type II in vivo and in vitro through the ROS-dependent mitochondrial signalling pathway. *J. Cell. Mol. Med.*18 (2014) 2198–2212.
- [30] Guo, S.-X., Zhou, H.-L., Huang, C.-L., You, C.-G., et al., Astaxanthin Attenuates Early Acute Kidney Injury Following Severe Burns in Rats by Ameliorating Oxidative Stress and Mitochondrial-Related Apoptosis. *Mar. Drugs*13(2015)2105–2123.